Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02407 高視醫療
Listing Date2022/12/12
Listing Price51.400
  • 48.800 +0.800 (+1.667%)    Sink Below Listing Price
  • 15-min delayed, last update: 24/03/2023 18:00
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    1 lot
  • One Lot Success Rate

Gaush Meditech Ltd is the largest domestic player and the fourth largest player in terms of revenue in 2021 with a market share of 6.7% in China’s ophthalmic medical device market with over 20 years of track record.


Its product offering covers all seven ophthalmology sub-specialties where ophthalmic medical devices are utilized for their diagnosis, treatment or surgeries, being vitreoretinal diseases, cataracts, refractive surgery, glaucoma, ocular surface diseases, optometry and pediatric ophthalmology. Its product portfolio comprised Distribution Products of its brand partners and Proprietary Products which it develops and manufactures.


For the six months ended June 30, 2022, the revenue contribution of its Distribution Products accounted for 70.5% of revenue from sales of products. It had collaborated with 19 overseas brand partners including Heidelberg, Schwind and Optos.


As of 20 Nov 2022, the Group had registered ten invention patents and 20 utility patents in China. over 4,000 end customers in China including over 1,200 Class III hospitals and 1,500 Class II hospitals. It had assisted brand partners to obtain the NMPA registration of 72 products.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot100
No. of Offer Shares13.07M shares
No. of International Offer Shares11.76M shares
No. of HK Offer Shares1.31M shares
Offer Price$51.40
Stock Code2407
Sponsor(s)Morgan Stanley Asia Limited, Haitong International Capital Limited
Underwriter(s)Morgan Stanley Asia Limited, Haitong International Securities Company Limited, Daiwa Capital Markets Hong Kong Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Maxa Capital Limited, Sinomax Securities Limited
Application PeriodNov 30 (Wed) - noon, Dec 05 (Mon)
Price Determination Date--
Result Announcement DateOn or before Dec 09 (Fri)
Result Announcement DateOn or before Dec 09 (Fri)
Dealings in Shares commence onDec 12, 2022. (Mon)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$51.40
NAV / share ($)$1.75 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 51.4, the net proceeds raised would be HKD 283.10M, of which
38.2% : Improve research and development capability and accelerate the commercialization of patents
29% : Improve production capacity and strengthen manufacturing capabilities
9.5% : Expand sales and marketing
10.6% : Working capital
12.7% : Repay interest-bearing borrowings
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.